Amsterdam-based SERDA Therapeutics, a joint venture company between Smith & Nephew International and NLC, announced that it has completed a €2M funding round, led by NLC Health Impact Fund.
The funding will propel the development of SERDA’s enzymatic wound debridement product, SN514.
With a successful Investigational New Drug (IND) submission, the company is gearing towards commercialisation with a Phase 1 clinical trial underway, followed by a Phase IIa study on burn wounds later this year.
Supported by the US Army’s medical research division, this marks an “important step” in making SERDA’s wound care solutions accessible to those in need.
What does SERDA Therapeutics offer?
Founded in 2020, SERDA Therapeutics is developing a proprietary product for wound debridement tailored to address severe burn injuries and chronic ulcers, such as pressure ulcers, open leg wounds, and diabetic foot ulcers.
Gabor Heltovics, CEO of SERDA, says, “Our mission at SERDA is to revolutionise wound debridement and improve the lives of those suffering from such conditions.”
“Our enzymatic debridement technology is being developed to combine exceptional long-term stability with fast removal of damaged tissue, significantly reducing healing time and discomfort. This approach would not only speed up recovery but also improve the quality of life for patients dealing with chronic conditions and burn injuries.”
Millions worldwide endure chronic and burn wounds, worsened by aging and diabetes. Traditional methods like surgery and enzymatic debridement are costly, painful, and often ineffective.
“SERDA’s innovative approach to wound care has the potential to significantly reduce both the healthcare burden of chronic wounds and the personal impact on patients,” says, Jaap Haemers, Investment Manager at NLC.
“We are excited to support SERDA as they move closer to bringing this vital technology to market,” adds Haemers.
Brief about the NLC HealthImpact Fund
The NLC Health Impact Fund, NLC’s latest and largest fund to date, is dedicated to investing in early-stage healthcare innovations. It aims to support ventures at different maturity levels by providing initial and follow-on funding.
The fund offers investors access to a diverse portfolio of impactful healthtech ventures, capturing high return potential in the early stage. Currently, NLC is raising funds for the second close of the Health Impact fund.
01
Empowering Ukrainian Startups: Highlights from the PowerUp Ukraine 2024 Conference